Schedule 13G ownership disclosure
Karyopharm Therapeutics Inc
Common Stock · CUSIP: 48576U205
Event date: 2025-09-30
- Filing-level shares
- 408,222
- Percent of class
- 4.70%
- The Vanguard Group
Shares: 408,222 · Class: 4.70%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000102909-25-000154
- Form type
- SCHEDULE 13G/A
- Filer
- Karyopharm Therapeutics Inc.
- CIK
- CIK 1503802
- Filed
- Oct 30, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership